Mesoporous Silica Particles Retain Their Structure and Function while Passing through the Gastrointestinal Tracts of Mice and Humans.
biostability
gastrointestinal tract
mesoporous silica particles
porcine pancreatic α-amylase
protein adsorption
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
02 Feb 2023
02 Feb 2023
Historique:
entrez:
2
2
2023
pubmed:
3
2
2023
medline:
3
2
2023
Statut:
aheadofprint
Résumé
Mesoporous silica particles (MSPs) can be used as food additives, clinically for therapeutic applications, or as oral delivery vehicles. It has also been discussed to be used for a number of novel applications including treatment for diabetes and obesity. However, a major question for their possible usage has been if these particles persist structurally and retain their effect when passing through the gastrointestinal tract (GIT). A substantial breaking down of the particles could reduce function and be clinically problematic for safety issues. Hence, we investigated the biostability of MSPs of the SBA-15 kind prepared at large scales (100 and 1000 L). The MSPs were orally administered in a murine model and clinically in humans. A joint extraction and calcination method was developed to recover the MSPs from fecal mass, and the MSPs were characterized physically, structurally, morphologically, and functionally before and after GIT passage. Analyses with N
Identifiants
pubmed: 36731867
doi: 10.1021/acsami.2c16710
pmc: PMC9951217
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Nanomedicine (Lond). 2014 Jul;9(9):1353-62
pubmed: 24471500
J Chromatogr A. 2016 Feb 5;1432:92-100
pubmed: 26787162
Angew Chem Int Ed Engl. 2016 Jul 25;55(31):8806-15
pubmed: 27303916
Small. 2009 Dec;5(23):2722-9
pubmed: 19780070
J Physiol. 1910 Mar 8;39(6):411-28
pubmed: 16992995
ACS Nano. 2014 Oct 28;8(10):10455-60
pubmed: 25264601
ACS Appl Mater Interfaces. 2015 Oct 7;7(39):21682-9
pubmed: 26371804
Chem Rev. 2013 Jun 12;113(6):4216-313
pubmed: 23289428
FASEB J. 1997 Sep;11(11):835-41
pubmed: 9285481
Eur J Pharm Biopharm. 2016 Nov;108:220-225
pubmed: 27648957
Langmuir. 2015 Jun 16;31(23):6457-62
pubmed: 26013363
Biomaterials. 2008 Oct;29(30):4045-55
pubmed: 18675454
Adv Drug Deliv Rev. 2013 May;65(5):689-702
pubmed: 22921598
Nanomedicine. 2015 Nov;11(8):1915-24
pubmed: 26238077
J Pharm Sci. 2012 Feb;101(2):444-63
pubmed: 21976048
Adv Healthc Mater. 2020 Jun;9(11):e2000057
pubmed: 32352221
PLoS One. 2020 Oct 2;15(10):e0240030
pubmed: 33007031
Nanomedicine (Lond). 2020 Jan;15(2):131-144
pubmed: 31933414
Nanomedicine. 2015 Jul;11(5):1117-32
pubmed: 25784453
ACS Appl Mater Interfaces. 2020 Mar 25;12(12):13598-13612
pubmed: 32077678
Br J Nutr. 2013 Sep 28;110(6):1024-30
pubmed: 23433536
Angew Chem Int Ed Engl. 2003 May 16;42(19):2182-5
pubmed: 12761755
EFSA J. 2018 Jan 17;16(1):e05088
pubmed: 32625658
J Food Sci. 2015 Nov;80(11):E2504-16
pubmed: 26496677
ACS Nano. 2012 Jul 24;6(7):5845-57
pubmed: 22721453
Adv Mater. 2012 Mar 22;24(12):1504-34
pubmed: 22378538
Nanomedicine (Lond). 2022 Jan;17(1):9-22
pubmed: 34854740
J Am Chem Soc. 2018 Mar 21;140(11):3892-3906
pubmed: 29533066
Science. 1998 Jan 23;279(5350):548-52
pubmed: 9438845
Nat Nanotechnol. 2021 Oct;16(10):1052
pubmed: 34625720
Adv Drug Deliv Rev. 2021 May;172:183-210
pubmed: 33705873
Nat Mater. 2009 Jul;8(7):543-57
pubmed: 19525947
J Mater Chem B. 2016 Nov 28;4(44):7146-7154
pubmed: 32263652
Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2050-5
pubmed: 17267609
Adv Mater. 2017 Mar;29(9):
pubmed: 28084658